Shanghai Newsummit Biopharma Group Co. is Drug Discovery in China that focus on development that business. Founded in 2001. They cover business area such as Provider, drug development process application, bio-pharmaceutical medicine, research, new drug, professional outsourcing service, pharmaceutical company, clinical trial, data management.
2001
( 23 years old in 2024 )
Development That
-
2nd Floor No.780
CaiLun Road, Zhangjiang Hi-Tech Park
Shanghai, Pudong District 201203
China
Private
Providerdrug development process applicationbio-pharmaceutical medicineresearchnew drugprofessional outsourcing servicepharmaceutical companyclinical trialdata management
* We use standard office opening hours in near Shanghai Newsummit Biopharma Group Co.'s location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Shanghai Newsummit Biopharma Group Co. is Drug Discovery business from China that founded in 2001 (23 years old in 2024), Shanghai Newsummit Biopharma Group Co. business is focusing on Development That.
Shanghai Newsummit Biopharma Group Co. headquarter office and corporate office address is located in 2nd Floor No.780 CaiLun Road, Zhangjiang Hi-Tech Park Shanghai, Pudong District 201203 China.
Shanghai Newsummit Biopharma Group Co. was founded in China.
In 2024, Shanghai Newsummit Biopharma Group Co. is currently focus on development that sector.
Above is snippet of Google Trends for "development that" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Shanghai Newsummit Biopharma Group Co., any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
